Passive and active targeting may be deployed independently, or the two approaches may be combined.
This strategy is designed for use in bone marrow, which is normally inaccessible to external radiation sources. In particular, the Nucleic Acid-Based Nanoconstructs for the Treatment of Cancer Center at Northwestern University is focused on the design and characterization of spherical nucleic acids for the delivery of RNA therapeutics to treat brain and prostate cancers.
These can be utilized for deep-tissue targets as well. Integrated development of innovative nanoparticle packages and active pharmaceutical ingredients will also enable exploration of a wider repertoire of active ingredients, no longer confined to those with acceptable pharmokinetic or biocompatibility behavior.
To overcome these limitations, nanoparticles are designed to bind to specific targets active targeting through the ligands that recognize particular receptors in target cells. Nanoparticles The history of nanoparticles starts in s with a polymer-drug conjugate that was designed by Jatzkewitz Jatzkewitz,followed by Bangham who discovered the liposomes in mids Bangham and Horne,Bangham et al.
Nanoparticle delivery vehicles can play a role at multiple points along this pathway. In essence, increasing efficacy while maintaining the current radiotherapy dosage and its subsequent toxicity to the surrounding tissue.
The publisher's final edited version of this article is available at J Drug Target See other articles in PMC that cite the published article.
A variety of targeting agents such as monoclonal antibodies mAbs and nucleic acids aptamers are also used to enhance tumoral uptake of nanoparticles.